Material Information (3176 MEDIGEN??????)

SEQ_NO	1	Date of announcement	2024/12/20	Time of announcement	16:25:54
Subject	Medigen and Oncolys Sign an Amendment regarding Sales of OBP-301				
Date of events	2024/12/20	To which item it meets	paragraph 53		

Statement

1.Date of occurrence of the event:2024/12/20
2.Company name:Medigen Biotechnology Corp.
3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):head office
4.Reciprocal shareholding ratios:N/A
5.Cause of occurrence:
Medigen and the Japanese publicly traded company Oncolys BioPharma (“Oncolys”, TSE stock code 4588), are jointly developing the oncolytic virus new drug OBP-301 (Telomelysin). Today (December 20, 2024), Medigen and Oncolys signed an Amendment (hereinafter ”the Amendment”). The Amendment amends the ”Strategic Alliance and License Agreement” dated in 2008 (hereinafter ”SALA”) between the two parties to establish a collaborative sales arrangement for OBP-301. Under the Amendment, Oncolys will be responsible for sales of OBP-301 in Japan, while Medigen will be responsible for sales of OBP-301 in Taiwan. Both parties will share a portion of the profits generated in their respective markets. Furthermore, the parties will explore potential market and discuss the possibility of Medigen for commercializing the product in Southeast Asia, China, Hong Kong, and Macau, depends on the progress of market development.
The 2008 SALA defined the responsibilities and profit-sharing framework for the joint development of OBP-301, with the goal of enhancing its value and licensing it to third parties for mutual benefit. The Amendment expands this collaboration to include business and sales efforts. Under the Amendment, Oncolys has granted Medigen an exclusive sales license for OBP-301 in Taiwan without any upfront or milestone payments. Medigen will proceed with the commercialization of OBP-301 in Taiwan based on the evaluation of OBP-301 development progress.
6.Countermeasures:none
7.Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.):
(1)The development timeline for new drugs is long, the investment costs are high, and success is not guaranteed. These factors may pose risks to investors, who should make careful judgments and invest cautiously.
(2)Our company shares the development costs of OBP-301 with Japan's Oncolys and will share in the future commercial benefits.
(3)Link to the announcement from Japan's Oncolys:
https://ssl4.eir-parts.net/doc/4588/tdnet/2542170/00.pdf